Literature DB >> 2696928

Severe pseudomembranous enterocolitis in a child: case report and literature review.

R J Zwiener1, W M Belknap, R Quan.   

Abstract

Antibiotic-associated pseudomembranous enterocolitis (PMC), an inflammatory gastrointestinal disease mediated by toxins produced by Clostridium difficile, is increasingly recognized in the pediatric population. We report a case of fulminant PMC in an otherwise normal 2 1/2-year-old child after antibiotic therapy given for a routine childhood illness. The patient had debilitating colitis marked by severe diarrhea, a generalized electrolyte derangement, an extreme protein-losing enteropathy state, rectal prolapse, ascites, pleural effusion, varicella and multiple relapses. The child required specific antimicrobial therapy as well as aggressive supportive care to achieve recovery. A review of the literature for pediatric cases of PMC revealed reported cases in all age groups; the youngest was 5 days old. There were 9 deaths in 43 cases for a mortality rate of about 20%. All but 2 of the cases were associated with antibiotic therapy. The antibiotics most frequently implicated were ampicillin (15), penicillin (11), cephalosporins (7), amoxicillin (6) and clindamycin (5). The onset of symptoms of PMC can begin at any time while the child is taking an antibiotic or up to 21 days after it is discontinued. Children with underlying gastrointestinal motility disorders such as Hirschsprung's disease are predisposed to PMC. Fulminant PMC is a serious but uncommon infectious disease of infancy and childhood, occurring as a complication of routine antibiotic therapy for common childhood illnesses.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2696928     DOI: 10.1097/00006454-198912000-00010

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  14 in total

1.  Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models.

Authors:  Jennifer Steele; Kevin Chen; Xingmin Sun; Yongrong Zhang; Haiying Wang; Saul Tzipori; Hanping Feng
Journal:  J Infect Dis       Date:  2011-12-05       Impact factor: 5.226

Review 2.  Clindamycin as an antimalarial drug: review of clinical trials.

Authors:  Bertrand Lell; Peter G Kremsner
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

3.  Mouse relapse model of Clostridium difficile infection.

Authors:  Xingmin Sun; Haiying Wang; Yongrong Zhang; Kevin Chen; Barbara Davis; Hanping Feng
Journal:  Infect Immun       Date:  2011-05-16       Impact factor: 3.441

Review 4.  Rational prescribing of antibacterials in ambulatory children.

Authors:  J E Hoppe
Journal:  Pharmacoeconomics       Date:  1996-12       Impact factor: 4.981

Review 5.  Rectal Prolapse in Children: Significance and Management.

Authors:  Kristen Cares; Mohammad El-Baba
Journal:  Curr Gastroenterol Rep       Date:  2016-05

Review 6.  Use of ciprofloxacin during breastfeeding.

Authors:  Yusuf Cem Kaplan; Gideon Koren
Journal:  Can Fam Physician       Date:  2015-04       Impact factor: 3.275

7.  Nosocomial outbreak of Clostridium difficile diarrhea in a pediatric service.

Authors:  A Ferroni; J Merckx; T Ancelle; B Pron; E Abachin; F Barbut; J Larzul; P Rigault; P Berche; J L Gaillard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-12       Impact factor: 3.267

8.  Heterogeneity of Clostridium difficile isolates from infants.

Authors:  A Collignon; L Ticchi; C Depitre; J Gaudelus; M Delmée; G Corthier
Journal:  Eur J Pediatr       Date:  1993-04       Impact factor: 3.183

Review 9.  The clinical significance of antibiotic-associated pseudomembranous colitis in the 1990s.

Authors:  M Andréjak; J L Schmit; A Tondriaux
Journal:  Drug Saf       Date:  1991 Sep-Oct       Impact factor: 5.606

Review 10.  The impact of Clostridium difficile on paediatric surgical practice: a systematic review.

Authors:  D Mc Laughlin; F Friedmacher; P Puri
Journal:  Pediatr Surg Int       Date:  2014-07-10       Impact factor: 1.827

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.